**5.3.86 Verapamil**

The calcium channel antagonist verapamil showed no beneficial effect in a clinical trail in ALS patients (Miller et al., 1996).

### **5.3.87 Xaliproden (SR57746)**

The 5HT1R agonist xaliproden is neurotrophic and neuroprotective. It has been evaluated in phase II/III trials, which showed modest effects on vital capacity, but not on survival of ALS patients (Lacomblez et al., 2004; Meininger et al., 2004).
